Rapid molecular detection of tuberculosis and rifampin resistance.
BACKGROUND
Global control of tuberculosis is hampered by slow, insensitive diagnostic methods, particularly for the detection of drug-resistant forms and in patients with human immunodeficiency virus infection. Early detection is essential to reduce the death rate and interrupt transmission, but the complexity and infrastructure needs of sensitive methods limit their accessibility and effect.


METHODS
We assessed the performance of Xpert MTB/RIF, an automated molecular test for Mycobacterium tuberculosis (MTB) and resistance to rifampin (RIF), with fully integrated sample processing in 1730 patients with suspected drug-sensitive or multidrug-resistant pulmonary tuberculosis. Eligible patients in Peru, Azerbaijan, South Africa, and India provided three sputum specimens each. Two specimens were processed with N-acetyl-L-cysteine and sodium hydroxide before microscopy, solid and liquid culture, and the MTB/RIF test, and one specimen was used for direct testing with microscopy and the MTB/RIF test.


RESULTS
Among culture-positive patients, a single, direct MTB/RIF test identified 551 of 561 patients with smear-positive tuberculosis (98.2%) and 124 of 171 with smear-negative tuberculosis (72.5%). The test was specific in 604 of 609 patients without tuberculosis (99.2%). Among patients with smear-negative, culture-positive tuberculosis, the addition of a second MTB/RIF test increased sensitivity by 12.6 percentage points and a third by 5.1 percentage points, to a total of 90.2%. As compared with phenotypic drug-susceptibility testing, MTB/RIF testing correctly identified 200 of 205 patients (97.6%) with rifampin-resistant bacteria and 504 of 514 (98.1%) with rifampin-sensitive bacteria. Sequencing resolved all but two cases in favor of the MTB/RIF assay.


CONCLUSIONS
The MTB/RIF test provided sensitive detection of tuberculosis and rifampin resistance directly from untreated sputum in less than 2 hours with minimal hands-on time. (Funded by the Foundation for Innovative New Diagnostics.)
Boehme
Catharina C
CC
Foundation for Innovative New Diagnostics, Geneva, Switzerland. catharina.boehme@finddiagnostics.org
Nabeta
Pamela
P
Hillemann
Doris
D
Nicol
Mark P
MP
Shenai
Shubhada
S
Krapp
Fiorella
F
Allen
Jenny
J
Tahirli
Rasim
R
Blakemore
Robert
R
Rustomjee
Roxana
R
Milovic
Ana
A
Jones
Martin
M
O'Brien
Sean M
SM
Persing
David H
DH
Ruesch-Gerdes
Sabine
S
Gotuzzo
Eduardo
E
Rodrigues
Camilla
C
Alland
David
D
Perkins
Mark D
MD
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics; D012321:DNA-Directed RNA Polymerases; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests / Q000379:methods; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics; D016133:Polymerase Chain Reaction / Q000295:instrumentation / Q000379:methods*; D011446:Prospective Studies; D012015:Reference Standards; D012293:Rifampin / Q000494:pharmacology*; D012680:Sensitivity and Specificity; D013183:Sputum / Q000382:microbiology; D014376:Tuberculosis / Q000175:diagnosis / Q000382:microbiology*; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis* / Q000382:microbiology; D055815:Young Adult
D000995:Antitubercular Agents; D001426:Bacterial Proteins; C505805:rpoB protein, Mycobacterium tuberculosis; D012321:DNA-Directed RNA Polymerases; D012293:Rifampin
J Clin Microbiol. 2010 Oct;48(10):3551-7
20720033
Lancet. 2007 Jun 16;369(9578):2042-2049
17574096
PLoS One. 2007 Aug 22;2(8):e757
17712405
Clin Chem. 2005 May;51(5):882-90
15746302
Nature. 2006 Nov 23;444 Suppl 1:73-9
17159896
JAMA. 2008 Jul 23;300(4):423-30
18647985
J Clin Microbiol. 2001 Nov;39(11):4131-7
11682541
Int J Tuberc Lung Dis. 2006 Aug;10(8):838-43
16898366
J Clin Microbiol. 2010 Jan;48(1):229-37
19864480
Biometrics. 1986 Mar;42(1):121-30
3719049
Nat Biotechnol. 1998 Apr;16(4):359-63
9555727
Int J Tuberc Lung Dis. 1998 Nov;2(11):869-76
9848606
Bull World Health Organ. 2007 May;85(5):327
17639210
Am Rev Respir Dis. 1968 Aug;98(2):295-6
4299186
FEMS Immunol Med Microbiol. 2009 Jul;56(2):103-11
19416361
Lancet. 2006 Nov 4;368(9547):1554-6
17084741
Int J Tuberc Lung Dis. 2009 Jul;13(7):799-800
19555526
Int J Tuberc Lung Dis. 2005 Dec;9(12):1409-11
16466066
J Clin Microbiol. 2010 Jul;48(7):2495-501
20504986
J Infect Dis. 2007 Aug 15;196 Suppl 1:S15-27
17624822
Clin Chem. 2003 Jan;49(1):1-6
12507953